Hurt Aeron C
WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
Department of Microbiology and Immunology, University of Melbourne, Parkville, VIC 3010, Australia.
Trop Med Infect Dis. 2019 Apr 18;4(2):67. doi: 10.3390/tropicalmed4020067.
Influenza antivirals will play a critical role in the treatment of outpatients and hospitalised patients in the next pandemic. In the past decade, a number of new influenza antivirals have been licensed for seasonal influenza, which can now be considered for inclusion into antiviral stockpiles held by the World Health Organization (WHO) and individual countries. However, data gaps remain regarding the effectiveness of new and existing antivirals in severely ill patients, and regarding which monotherapy or combinations of antivirals may yield the greatest improvement in outcomes. Regardless of the drug being used, influenza antivirals are most effective when treatment is initiated early in the course of infection, and therefore in a pandemic, effective strategies which enable rapid diagnosis and prompt delivery will yield the greatest benefits.
在下一次大流行中，流感抗病毒药物将在门诊患者和住院患者的治疗中发挥关键作用。在过去十年中，一些新型流感抗病毒药物已获许可用于季节性流感，现在可考虑将其纳入世界卫生组织（WHO）和各个国家持有的抗病毒药物储备中。然而，关于新的和现有的抗病毒药物在重症患者中的有效性，以及哪种单一疗法或抗病毒药物组合可能带来最大的疗效改善，仍然存在数据空白。无论使用何种药物，流感抗病毒药物在感染过程早期开始治疗时最为有效，因此在大流行中，能够实现快速诊断和及时给药的有效策略将带来最大益处。
